The busy week for the idiopathic pulmonary fibrosis (IPF) space has continued apace with the news that Roche is selling off rights to one of the two drugs currently approved for the debilitating and fatal lung disease.
Spotlight On IPF Successors To Esbriet And Ofev
Only two drugs have been approved for the progressive fibrosing interstitial lung disease but the pipeline is full of promising, and hopefully more tolerable, candidates.
